Evidence map›Paper›PMID 38746870›Full record

ArticleOncoimmunology2024

Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.

Douglas C Chung, Maryam Ghaedi, Kathrin Warner, Azin Sayad, Samuel D Saibil, Marcus Q Bernardini, Blaise A Clarke, Patricia A Shaw, Marcus O Butler, Alexandra Easson and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Douglas C ChungPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-7971-3051
Maryam GhaediPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Kathrin WarnerPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Azin SayadPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Samuel D SaibilPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Marcus Q BernardiniDivision of Gynecologic Oncology, University Health Network, Toronto, ON, Canada.ORCID 0000-0001-7022-8308
Blaise A ClarkeDivision of Gynecologic Oncology, University Health Network, Toronto, ON, Canada.
Patricia A ShawDivision of Gynecologic Oncology, University Health Network, Toronto, ON, Canada.
Marcus O ButlerPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-9840-7057
Alexandra EassonDepartment of Surgical Oncology, University Health Network, Toronto, ON, Canada.
Sorana MorrissyDepartment of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.ORCID 0000-0001-8526-562X
Ben X WangPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Linh NguyenPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Pamela S OhashiPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-2915-9317
Nicolas JacquelotDepartment of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.ORCID 0000-0003-0282-1892

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The innate lymphoid cell (ILC) family is composed of heterogeneous innate effector and helper immune cells that preferentially reside in tissues where they promote tissue homeostasis. In cancer, they have been implicated in driving both pro- and anti-tumor responses. This apparent dichotomy highlights the need to better understand differences in the ILC composition and phenotype within different tumor types that could drive seemingly opposite anti-tumor responses. Here, we characterized the frequency and phenotype of various ILC subsets in melanoma metastases and primary epithelial ovarian tumors. We observed high PD-1 expression on ILC subsets isolated from epithelial ovarian tumor samples, while ILC populations in melanoma samples express higher levels of LAG-3. In addition, we found that the frequency of cytotoxic ILCs and NKp46

Indexed as

Carcinoma, Ovarian EpithelialImmunity, InnateLymphocytes, Tumor-InfiltratingMelanomaOvarian NeoplasmsAntigens, CDDendritic CellsFemaleHumansLymphocyte Activation Gene 3 ProteinLymphocyte SubsetsNatural Cytotoxicity Triggering Receptor 1Neoplasms, Glandular and EpithelialProgrammed Cell Death 1 ReceptorTumor MicroenvironmentAntigens, CDLymphocyte Activation Gene 3 ProteinNatural Cytotoxicity Triggering Receptor 1Programmed Cell Death 1 ReceptorEpithelial ovarian cancerinnate lymphoid cellsLAG-3melanomamyeloid cellsNK cellsPD-1T cells

Identifiers

PMID38746870
PMCPMC11093043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.